Evelo Biosciences
- Founded: 2015
- Location: Cambridge, MA
- Employee range: 50 - 200
- Clinical stage: Clin0
- Therapy area: inflammation
- Drug types: IMM, NEU
- Lead product: EDP2939
- Product link: https://evelobio.com/our-pipeline/
- Funding: $25.5M stock Jul 2023; $79M stock May 2022; $45M stock Jun 2020; $45M debt Jul 2019; $85M IPO May 2018; $50M B Jul 2017
evelobio.com linkedin.com job board
Short description:
Microbiomic cancer treatments
Drug notes:
2 undisclosed programs RD neuroinflammation, metabolic conditions
Long description:
Evelo Biosciences is developing drugs that target the small intestine to modulate the body’s immune response. Cells in the small intestine are connected to the immune system, metabolic system and the neurological system making them important for governing inflammation within the body. To target the small intestine to treat disease, Evelo created their SINTAX platform, where they use biological insights from the intestinal axis to develop orally-delivered medicines. While the medicines act in the small intestine they can have a systemic therapeutic effect. Evelo recently received positive Phase 2 clinical data for their lead candidate, EDP1814, in patients with psoriasis, a skin disease, showing how peripheral tissues can be targeted by drugs that act in the intestine.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com